Crossmark

High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study

Crossref DOI link: https://doi.org/10.1016/j.gastre.2025.502379

Published Print: 2025-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Andrés, Laura

Iborra, Marisa

Vicente, Raquel

Arias, Lara

Nos, Pilar

Royo-Esteban, Ana

Sicilia, Beatriz
License Information

Text and Data Mining valid from 2025-07-01

Text and Data Mining valid from 2025-07-01

stm-asf valid from 2025-07-01

stm-asf valid from 2025-07-01

stm-asf valid from 2025-07-01

stm-asf valid from 2025-07-01

stm-asf valid from 2025-07-01
More Information

This article is maintained by: Elsevier

Article Title: High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: Results of a Spanish multicentre observational study

Journal Title: Gastroenterología y Hepatología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.gastre.2025.502379

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.gastrohep.2025.502379

Content Type: article

Copyright: © 2025 Elsevier España, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Document is current

Any future updates will be listed below